Livzon Pharmaceutical Group

Livzon Pharmaceutical Group EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Livzon Pharmaceutical Group (000513.SZ) as of Nov 4, 2026 is 2.62 B CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 3.03 B CNY — a change of -13.43% (lower).

EBITDA

2.62 BCNY

YoY

-13.43%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Livzon Pharmaceutical Group is 2025 2.62 B CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Livzon Pharmaceutical Group was 2024 3.03 B CNY. It decreases by -13.43% lower compared to the previous year.

The Livzon Pharmaceutical Group EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
1.39 B CNY
Jan 1, 2019
1.87 B CNY
Jan 1, 2020
2.63 B CNY
Jan 1, 2021
2.44 B CNY
Jan 1, 2022
2.66 B CNY
Jan 1, 2023
2.87 B CNY
Jan 1, 2024
3.03 B CNY
Jan 1, 2025
2.62 B CNY
The Livzon Pharmaceutical Group EBITDA history
YEAREBITDAYoY
2.62 BCNY-13.43%
3.03 BCNY+5.56%
2.87 BCNY+8.02%
2.66 BCNY+9.08%
2.44 BCNY-7.39%
2.63 BCNY+40.81%
1.87 BCNY+34.31%
1.39 BCNY-75.64%
5.71 BCNY+505.61%
943.32 MCNY+28.20%
735.80 MCNY+17.26%
627.51 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Livzon Pharmaceutical Group Stock analysis

What does Livzon Pharmaceutical Group do? Livzon Pharmaceutical Group Inc is a large Chinese company specializing in the development and marketing of pharmaceutical products. It was founded in 1985 and is headquartered in Zhuhai, a city in the southern Chinese province of Guangdong. Livzon is now one of the largest companies in the Chinese pharmaceutical industry and also has a good international reputation. Business model and divisions: The company's business model is diverse and includes research and development, production and distribution of bio-pharmaceuticals, active pharmaceutical ingredients (APIs), generics, traditional Chinese medicines, and diagnostics. Livzon is divided into various divisions, including the bio-pharmaceutical division, the generics division, and the traditional Chinese medicine division. These divisions have different focuses and products. Bio-pharmaceuticals: The bio-pharmaceutical division focuses on the research and development of biopharmaceutical products based on biological processes. The goal is to develop new treatment options for serious diseases such as cancer, autoimmune diseases, or infectious diseases. The most well-known products include the cancer drug Lyophilized Powder Injection and the treatment for autoimmune diseases Levamisole Hydrochloride. Generics: In the generics division, Livzon produces patent-free drugs that offer an alternative to expensive original medications. The company places special emphasis on testing and certifying the quality of its products. Livzon has an extensive range of generics with active ingredients for various diseases, such as hypertension, diabetes, and gastrointestinal diseases. Traditional Chinese medicine: Livzon is one of the few modern pharmaceutical companies specializing in the development and marketing of traditional Chinese medicines. Plant extracts and components derived from animal products are used for therapeutic purposes. The most well-known products include Yiganerjing Cream, a remedy for eczema, and Huoluo Oil, used for joint pain. Products: Livzon has introduced a variety of products to the market in recent years that have gained international recognition. Particularly notable are the products in the bio-pharmaceutical division, which are used in cancer therapy. Additionally, generics and traditional Chinese medicines are important components of the product portfolio. As one of the leading companies in the Chinese pharmaceutical industry, Livzon strives to meet the needs of its customers and continuously expand its offerings. Furthermore, the company is investing heavily in expanding its research and development department to develop innovative products that better meet the needs of patients. Livzon Pharmaceutical Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Livzon Pharmaceutical Group stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Livzon Pharmaceutical Group is 2.62 B CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Livzon Pharmaceutical Group changed from 3.03 B CNY to 2.62 B CNY, representing a -13.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Livzon Pharmaceutical Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Livzon Pharmaceutical Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Livzon Pharmaceutical Group

All Key Metrics — Livzon Pharmaceutical Group